prikaz prve stranice dokumenta Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients
  Preuzmi
PDF 895.43 KB
Znanstveni rad - Izvorni znanstveni rad
Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients
Journal of Personalized Medicine, 14 (2024), 3; 278. https://doi.org/10.3390/jpm14030278
Vučinić, Damir; Skočilić, Iva; Golčić, Marin; Dobrila-Dintinjana, Renata; Kolak, Maja; Jerković, Ivona; Tesar, Eleonora Cini; Ferari, Ani Mihaljević; Ređović, Arnela; Marušić, Jasna; Kolovrat, Doris; Mikolašević, Ivana

Citirajte ovaj rad

Vučinić, D., Skočilić, I., Golčić, M., Dobrila Dintinjana, R., Kolak, M., Jerković, I. ... Mikolašević, I. (2024). Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients. Journal of Personalized Medicine, 14. (3). doi: 10.3390/jpm14030278

Vučinić, Damir, et al. "Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients." Journal of Personalized Medicine, vol. 14, br. 3, 2024. https://doi.org/10.3390/jpm14030278

Vučinić, Damir, Iva Skočilić, Marin Golčić, Renata Dobrila Dintinjana, Maja Kolak, Ivona Jerković, Eleonora Cini Tesar, et al. "Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients." Journal of Personalized Medicine 14, br. 3 (2024). https://doi.org/10.3390/jpm14030278

Vučinić, D., et al. (2024) 'Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients', Journal of Personalized Medicine, 14(3). doi: 10.3390/jpm14030278

Vučinić D, Skočilić I, Golčić M, Dobrila Dintinjana R, Kolak M, Jerković I, i sur.. Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients. Journal of Personalized Medicine [Internet]. 01.03.2024. [pristupljeno 01.05.2024.];14(3). doi: 10.3390/jpm14030278

D. Vučinić, et al., "Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients", Journal of Personalized Medicine, vol. 14, br. 3, Ožujak 2024. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:184:957807. [Citirano: 01.05.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:184:957807
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Effectiveness and Safety of Immune Checkpoint Inhibitors in Older Cancer Patients
AutorDamir Vučinić https://orcid.org/0000-0002-5804-0799
AutorIva Skočilić
AutorMarin Golčić
AutorRenata Dobrila-Dintinjana
AutorMaja Kolak
AutorIvona Jerković
AutorEleonora Cini Tesar
AutorAni Mihaljević Ferari
AutorArnela Ređović
AutorJasna Marušić
AutorDoris Kolovrat
AutorIvana Mikolašević
Autorova ustanovaSveučilište u Rijeci
Medicinski fakultet
(Katedra za onkologiju i radioterapiju)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Onkologija
Sažetak (engleski)
Background: The development of immunotherapy checkpoint inhibitors (ICIs) has revolutionized cancer care. However, old patients are underrepresented in most clinical trials, although they represent a significant proportion of real-world patients. We aimed to evaluate the effectiveness and safety of ICIs in patients older than the age of 70. Methods: We performed a retrospective chart review of 145 patients aged 70 or older treated with ICIs for metastatic or unresectable cancer. Results: Median progression-free survival (PFS) was 10.4 months (95% CI 8.6–13.7), with no differences between octogenarians and septuagenarians (p = 0.41). Female gender (p = 0.04) and first-line treatment setting (p < 0.0001) were associated with a longer median PFS. Median overall survival (OS) was 20.7 months (95% CI 13.5–35.0 months), with no difference based on performance status, cancer site, gender, or between septuagenarians and octogenarians (all p > 0.005). Patients treated with ICIs in the first-line setting reported longer OS compared to treatment in the second-line setting (p < 0.001). Discontinuation of ICIs due to adverse effects was associated with both shorter PFS (p = 0.0005) and OS (p < 0.0001). Conclusion: The effectiveness of ICIs in older cancer patients primarily depends on the line of treatment and treatment discontinuation. Octogenarians experienced similar treatment responses, PFS, OS, and adverse effects compared to septuagenarians.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran - međunarodna recenzija
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaJournal of Personalized Medicine
Brojčani podacivol. 14, br. 3, 278
e-ISSN2075-4426
DOIhttps://doi.org/10.3390/jpm14030278
URN:NBNurn:nbn:hr:184:957807
Datum objave publikacije2024-03-01
URL dokumentahttps://www.mdpi.com/2075-4426/14/3/278
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2024-03-05 08:45:56